Ray Dalio's SRPT Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 352,275 shares of Sarepta Therapeutics, Inc. (SRPT) worth $6.79 M, representing 0.03% of the portfolio. First purchased in 2021-Q1, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Ray Dalio has maintained a strategic position in SRPT, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 352,275 shares. Largest reduction occurred in Q4 2022, reducing 40,473 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2021 | +4,208 | New Buy | 4,208 | $74.62 |
| Q2 2021 | -370 | Reduce 8.79% | 3,838 | $77.64 |
| Q3 2021 | -3,838 | Sold Out | 0 | $0.00 |
| Q1 2022 | +4,374 | New Buy | 4,374 | $78.19 |
| Q2 2022 | +121,144 | Add 2769.64% | 125,518 | $74.96 |
| Q3 2022 | -27,110 | Reduce 21.60% | 98,408 | $110.54 |
| Q4 2022 | -40,473 | Reduce 41.13% | 57,935 | $129.58 |
| Q1 2023 | -27,465 | Reduce 47.41% | 30,470 | $137.83 |
| Q2 2023 | +386 | Add 1.27% | 30,856 | $114.52 |
| Q3 2023 | +19,608 | Add 63.55% | 50,464 | $121.22 |
| Q4 2023 | -24,076 | Reduce 47.71% | 26,388 | $96.43 |
| Q1 2024 | -3,166 | Reduce 12.00% | 23,222 | $129.46 |
| Q2 2024 | -23,222 | Sold Out | 0 | $0.00 |
| Q4 2024 | +5,245 | New Buy | 5,245 | $121.59 |
| Q1 2025 | +14,575 | Add 277.88% | 19,820 | $63.82 |
| Q2 2025 | -19,820 | Sold Out | 0 | $0.00 |
| Q3 2025 | +352,275 | New Buy | 352,275 | $19.27 |
Ray Dalio's Sarepta Therapeutics Investment FAQs
Ray Dalio first purchased Sarepta Therapeutics, Inc. (SRPT) in Q1 2021, acquiring 4,208 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held Sarepta Therapeutics, Inc. (SRPT) for 17 quarters since Q1 2021.
Ray Dalio's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q3 2025, adding 352,275 shares worth $6.79 M.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 352,275 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $6.79 M.
As of the Q3 2025 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.03% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 352,275 shares, as reported at the end of Q3 2025.